Topiramate Capsule, Extended · 5 active FDA presentation rows for this drug
Brand: QUDEXY XR
FDA lists Topiramate Capsule, Extended as To Be Discontinued (Upsher-Smith Laboratories, LLC).
No availability text on this FDA row.
Topiramate Capsule, Extended Release: To Be Discontinued
FDA availability text is not recorded on this row. 5 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Topiramate Capsule, Extended Release
- Manufacturer
- Upsher-Smith Laboratories, LLC
- Dosage Form
- Capsule, Extended Release
- Presentation
- Qudexy XR, Capsule, Extended Release, 50 mg (NDC 0245-1072-30)
- Package NDC
- 0245-1072-30
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Apr 24, 2025
- Last Updated
- Apr 24, 2025
- Therapeutic Category
- Neurology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
Full Drug Profile
topiramate
Side effects, interactions, warnings & more
Nearby, Other Topiramate Shortage Records
Topiramate Capsule, Extended Release
Upsher-Smith Laboratories, LLC
Capsule, Extended Release
Topiramate Capsule, Extended Release
Upsher-Smith Laboratories, LLC
Capsule, Extended Release
Topiramate Capsule, Extended Release
Upsher-Smith Laboratories, LLC
Capsule, Extended Release
Topiramate Capsule, Extended Release
Upsher-Smith Laboratories, LLC
Capsule, Extended Release
FDA reason on file: Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules. General shortage guidance lives on the tracker hub.